Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
10 Results for "
spinocerebellar ataxias
" in MedChemExpress (MCE) Product Catalog:
Products (10)
10 Results for "spinocerebellar ataxias" in MCE Product Catalog:
2
Target:
Research Areas:
Rimtuzalcap (CAD-1883) is a first-in-class selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels). Rimtuzalcap can be used for the research of movement disorders including essential tremor (ET) and spinocerebellar ataxia (SCA) .
Synonyms: NCD
Target:
Research Areas:
Naphthyridine carbamate dimer (NCD) is a molecular glue. Naphthyridine carbamate dimer induces designed structural changes in target functional DNA, thereby regulating its function. As a molecular glue, naphthyridine carbamate dimer stabilizes non-spontaneously formed GG homologous mismatched double-stranded DNA. Naphthyridine carbamate dimer reduces the formation of toxic RNA foci and regulates CGG repeat instability associated with fragile X syndrome and spinocerebellar ataxia type 31. Naphthyridine carbamate dimer can be used in research related to fragile X syndrome and spinocerebellar ataxia type 31 .
Target:
Research Areas:
NS13001 is a potent, selective, orally active allosteric positive modulator of SK channels (small conductance calcium-activated potassium channels). The EC50s are 1.8 and 0.14 μM for SK2 and SK3, respectively. NS13001 holds promise as a potential therapeutic agent for treatment of spinocerebellar ataxia type 2 (SCA2) and possibly other cerebellar ataxias .
Cat. No.: HY-163171
CAS No.: 1214569-31-9
Target:
Research Areas:
ARN 11391 is a selective enhancer of inositol triphosphate receptor type 1 (ITPR1). ARN 11391 can be used in the study of spinocerebellar ataxia .
Target:
Research Areas:
TDP1 Inhibitor-2 (compound 5) is a potent inhibitor for TDP1 (tyrosyl-DNA phosphodiesterase 1), with an IC50 of 99 nM. TDP1 Inhibitor-2 also can inhibit SCAN1 (spinocerebellar ataxia syndrome with axonal neuropathy), with an IC50 of 3.5 μM .
Cat. No.: HY-160884
CAS No.: 1470023-72-3
Target:
Research Areas:
DMT-2'-OMe-D-Ribitol phosphoramidite is a phosphoramidite monomer synthesized from (2R,3S,4S)-2-hydroxymethyl-4-methoxytetrahydrofuran-3-ol, used to introduce the Y34 abasic moiety into oligonucleotides for solid-phase oligonucleotide synthesis. DMT-2'-OMe-D-Ribitol phosphoramidite can be used for the research of huntington's disease, machado joseph disease (spinocerebellar ataxia 3) .
Cat. No.: HY-E70871
Target:
Research Areas:
TTBK2 is a tau tubulin kinase. Mutations in TTBK2 cause spinocerebellar ataxia type 11, a disorder exhibiting both loss of Purkinje cells and widespread deposition of tau. TTBK2 Recombinant Human Active Protein Kinase is a recombinant TTBK2 protein that can be used to study TTBK2-related functions .
Cat. No.: HY-173353
CAS No.: 420106-23-6
Target:
Research Areas:
ATXN1-MED15 PPI-IN-1 (compound 5755483) is an inhibitor of ATXN1/MED15. ATXN1-MED15 PPI-IN-1 binds to ATXN1 residues 99-163 and inhibits both the interaction between ATXN1 and MED15, as well as the dimerization of polyQ-expanded ATXN1. ATXN1-MED15 PPI-IN-1 can be used for study of Spinocerebellar ataxia type 1 .
Cat. No.: HY-109160R
CAS No.: 2167246-24-2
Synonyms: CAD-1883 (Standard)
Target:
Research Areas:
Rimtuzalcap (Standard) is the analytical standard of Rimtuzalcap (HY-109160). This product is intended for research and analytical applications. Rimtuzalcap (CAD-1883) is a first-in-class selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels). Rimtuzalcap can be used for the research of movement disorders including essential tremor (ET) and spinocerebellar ataxia (SCA) .
Cat. No.: HY-L086
3,759 compounds
Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.
MCE offers a unique collection of 3,759 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
